The DEEP project has received research funding from the European Union under the 7th Framework Programme

News

Performing a paediatric clinical study in Tunisia: interview to Prof. Mohamed Bejaoui

Marzo 25, 2016
|
Comments off
|

Paediatric trials have a default level of complexity, that is depending on regulatory, methodological, ethical and administrative issues, especially when they are registrative and international as DEEP-2 is.

DEEP-2 is, in fact, a multi-national and multi-center clinical trial involving not only a paediatric multi […]

Share
Read more →

7th DEEP General Assembly meeting in Padua (Italy)

Marzo 25, 2016
|
Comments off
|

After the sad decision to cancel the General Assembly Meeting in Tunis, due to the disorders which have occurred across the country, the 7th DEEP General Assembly (GA) will take place in Padua (Italy) on April 13th -15th, 2016 with the participation of the whole DEEP […]

Share
Read more →

DEEP-2: almost at the final rush

Marzo 25, 2016
|
Comments off
|

Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, the phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected […]

Share
Read more →

DEEP-3 at a glance: interview to Prof. Antje Neubert

Marzo 25, 2016
|
Comments off
|

DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major by conducting a multi-centre, multi-national, observational cohort study with both retrospective (using chart review) and prospective data […]

Share
Read more →